JP2007529714A - 遺伝子分析のための方法 - Google Patents

遺伝子分析のための方法 Download PDF

Info

Publication number
JP2007529714A
JP2007529714A JP2007502088A JP2007502088A JP2007529714A JP 2007529714 A JP2007529714 A JP 2007529714A JP 2007502088 A JP2007502088 A JP 2007502088A JP 2007502088 A JP2007502088 A JP 2007502088A JP 2007529714 A JP2007529714 A JP 2007529714A
Authority
JP
Japan
Prior art keywords
individual
risk
score
group
allele
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007502088A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007529714A5 (https=
Inventor
デビッド アール． コックス
マーク マクカミッシュ
Original Assignee
パーレジェン サイエンス インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by パーレジェン サイエンス インク． filed Critical パーレジェン サイエンス インク．
Publication of JP2007529714A publication Critical patent/JP2007529714A/ja
Publication of JP2007529714A5 publication Critical patent/JP2007529714A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/40—Population genetics; Linkage disequilibrium
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding

Landscapes

  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Databases & Information Systems (AREA)
  • Primary Health Care (AREA)
  • Data Mining & Analysis (AREA)
  • Signal Processing (AREA)
  • Artificial Intelligence (AREA)
  • Bioethics (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Evolutionary Computation (AREA)
  • Software Systems (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2007502088A 2004-03-05 2005-03-03 遺伝子分析のための方法 Withdrawn JP2007529714A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US55066204P 2004-03-05 2004-03-05
US56630204P 2004-04-28 2004-04-28
US59053404P 2004-07-22 2004-07-22
US10/956,224 US7127355B2 (en) 2004-03-05 2004-09-30 Methods for genetic analysis
PCT/US2005/007375 WO2005086770A2 (en) 2004-03-05 2005-03-03 Methods for genetic analysis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013151528A Division JP2013240344A (ja) 2004-03-05 2013-07-22 遺伝子分析のための方法

Publications (2)

Publication Number Publication Date
JP2007529714A true JP2007529714A (ja) 2007-10-25
JP2007529714A5 JP2007529714A5 (https=) 2008-04-17

Family

ID=34916521

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2007502088A Withdrawn JP2007529714A (ja) 2004-03-05 2005-03-03 遺伝子分析のための方法
JP2013151528A Pending JP2013240344A (ja) 2004-03-05 2013-07-22 遺伝子分析のための方法
JP2016016966A Pending JP2016082984A (ja) 2004-03-05 2016-02-01 遺伝子分析のための方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013151528A Pending JP2013240344A (ja) 2004-03-05 2013-07-22 遺伝子分析のための方法
JP2016016966A Pending JP2016082984A (ja) 2004-03-05 2016-02-01 遺伝子分析のための方法

Country Status (4)

Country Link
US (2) US7127355B2 (https=)
EP (1) EP1725967A4 (https=)
JP (3) JP2007529714A (https=)
WO (1) WO2005086770A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016155840A (ja) * 2009-09-29 2016-09-01 ノバルティス アーゲー Ｓ１ｐ受容体モジュレーターの投与計画
JP2019216732A (ja) * 2010-11-01 2019-12-26 ジェネンテック， インコーポレイテッド 多遺伝子スコアを用いた後期加齢性黄斑変性症への進行の予測
JPWO2022080389A1 (https=) * 2020-10-14 2022-04-21

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7127355B2 (en) * 2004-03-05 2006-10-24 Perlegen Sciences, Inc. Methods for genetic analysis
US20090087854A1 (en) * 2007-09-27 2009-04-02 Perlegen Sciences, Inc. Methods for genetic analysis
US20060166224A1 (en) * 2005-01-24 2006-07-27 Norviel Vernon A Associations using genotypes and phenotypes
US7421419B2 (en) * 2005-04-12 2008-09-02 Viziant Corporation System and method for evidence accumulation and hypothesis generation
CA2631621C (en) * 2005-11-29 2019-08-06 Cambridge Enterprise Limited Markers for breast cancer including rs2981582
MX2008011185A (es) * 2006-03-01 2008-09-10 Perlegen Sciences Inc Marcadores para adiccion.
US20110143344A1 (en) * 2006-03-01 2011-06-16 The Washington University Genetic polymorphisms and substance dependence
US9115389B2 (en) 2006-06-30 2015-08-25 Rosetta Genomics Ltd. Method for detecting a target nucleic acid comprising two portions using probes having a first portion complementary to the first portion of the target nucleic acid and a second portion substantially complementary to the second portion of the target nucleic acid
SI2084535T1 (sl) * 2006-09-08 2016-08-31 Richard Porwancher Postopek diagnosticiranja s pomočjo bioinformatike
US20080131887A1 (en) * 2006-11-30 2008-06-05 Stephan Dietrich A Genetic Analysis Systems and Methods
JP2010522537A (ja) * 2006-11-30 2010-07-08 ナビジェニクス インコーポレイティド 遺伝子分析系および方法
US20080228700A1 (en) 2007-03-16 2008-09-18 Expanse Networks, Inc. Attribute Combination Discovery
US20090012839A1 (en) * 2007-07-03 2009-01-08 American Express Travel Related Services Company, Inc. Determining Brand Affiliations
US20090043752A1 (en) 2007-08-08 2009-02-12 Expanse Networks, Inc. Predicting Side Effect Attributes
CA2700975A1 (en) * 2007-09-26 2009-04-02 Navigenics, Inc. Methods and systems for genomic analysis using ancestral data
US20090226912A1 (en) * 2007-12-21 2009-09-10 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with prostate cancer risk
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
US20090326832A1 (en) * 2008-06-27 2009-12-31 Microsoft Corporation Graphical models for the analysis of genome-wide associations
GB2478065A (en) * 2008-08-08 2011-08-24 Navigenics Inc Method and systems for personalized action plans
US8200509B2 (en) 2008-09-10 2012-06-12 Expanse Networks, Inc. Masked data record access
US7917438B2 (en) * 2008-09-10 2011-03-29 Expanse Networks, Inc. System for secure mobile healthcare selection
KR20110074527A (ko) * 2008-09-12 2011-06-30 네이비제닉스 인크. 복수의 환경 및 유전 위험 인자를 통합하기 위한 방법 및 시스템
US8255403B2 (en) 2008-12-30 2012-08-28 Expanse Networks, Inc. Pangenetic web satisfaction prediction system
US8386519B2 (en) 2008-12-30 2013-02-26 Expanse Networks, Inc. Pangenetic web item recommendation system
US8108406B2 (en) * 2008-12-30 2012-01-31 Expanse Networks, Inc. Pangenetic web user behavior prediction system
US20100169338A1 (en) * 2008-12-30 2010-07-01 Expanse Networks, Inc. Pangenetic Web Search System
US8463554B2 (en) 2008-12-31 2013-06-11 23Andme, Inc. Finding relatives in a database
US20120323600A1 (en) * 2009-05-07 2012-12-20 Pathway Genomics Genome-based drug management systems
US20110294681A1 (en) 2009-06-01 2011-12-01 Hinds David A Methods for breast cancer risk assessment
WO2012031207A2 (en) 2010-09-03 2012-03-08 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with prostate cancer risk
US9534256B2 (en) 2011-01-06 2017-01-03 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with risk of aggressive prostate cancer
US20130218581A1 (en) * 2011-04-26 2013-08-22 Selventa, Inc. Stratifying patient populations through characterization of disease-driving signaling
US20140378351A1 (en) * 2013-06-22 2014-12-25 Brian Meshkin System and method for processing genotype information relating to treatment with pain medication
AU2014306867B2 (en) 2013-08-12 2017-10-26 Genentech, Inc. Compositions and method for treating complement-associated conditions
EP3137503A1 (en) 2014-05-01 2017-03-08 Genentech, Inc. Anti-factor d antibody variants and uses thereof
EP3194627B1 (en) * 2014-09-18 2023-08-16 Illumina, Inc. Methods and systems for analyzing nucleic acid sequencing data
US10920279B2 (en) 2014-09-30 2021-02-16 Genetic Technologies Limited Method for modifying a treatment regimen of a human female subject
EP3543361A1 (en) * 2014-10-14 2019-09-25 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with colorectal cancer risk
US10152298B1 (en) * 2015-06-29 2018-12-11 Amazon Technologies, Inc. Confidence estimation based on frequency
WO2017075252A1 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibody variant conjugates and uses thereof
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
IL260777B (en) 2016-01-28 2022-09-01 Univ Melbourne Methods for assessing risk of developing colorectal cancer
US20170240965A1 (en) * 2016-02-22 2017-08-24 Cedars-Sinai Medical Center Methods for prognosing heart transplant
US10783997B2 (en) 2016-08-26 2020-09-22 International Business Machines Corporation Personalized tolerance prediction of adverse drug events
RU2678441C1 (ru) * 2018-07-02 2019-01-29 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ прогнозирования риска развития гипертонической болезни с учетом генетических и средовых факторов
EP4158067A4 (en) 2020-05-27 2024-09-25 Genetic Technologies Limited Methods of assessing risk of developing a severe response to coronavirus infection
MX2023002925A (es) * 2020-09-10 2023-09-29 Microgenesis Corp Metodos y composiciones relacionados con la evaluacion de afecciones inflamatorias relacionadas con la fecundidad.
US20250149176A1 (en) * 2023-11-08 2025-05-08 Optum Services (Ireland) Limited Model-based risk prediction and treatment pathway prioritization

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232398A1 (en) * 2002-03-28 2003-12-18 Macmurray James P. Use of ROC plots of genetic risk factor to predict risk of sporadic breast cancer

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3023A (en) * 1843-03-30 peters
US20020048749A1 (en) 1998-04-15 2002-04-25 Robert J. Lipshutz Methods for polymorphism identifcation and profiling
US5968770A (en) 1995-02-10 1999-10-19 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of cardiovascular disease using rchd523 as a target
US6274332B1 (en) 1995-12-22 2001-08-14 Univ. Of Utah Research Foundation Mutations in the KCNE1 gene encoding human minK which cause arrhythmia susceptibility thereby establishing KCNE1 as an LQT gene
US5817461A (en) 1996-01-03 1998-10-06 Hamilton Civic Hospitals Research Development Inc. Methods and compositions for diagnosis of hyperhomocysteinemia
ES2229781T3 (es) 1998-11-10 2005-04-16 Genset Metodos programas y aparatos para identificar regiones genomicas que albergan un gen asociado con un rasgo detectable.
US20040171056A1 (en) 1999-02-22 2004-09-02 Variagenics, Inc., A Delaware Corporation Gene sequence variations with utility in determining the treatment of disease, in genes relating to drug processing
JP2003521024A (ja) 1999-06-25 2003-07-08 ジェネサンス・ファーマシューティカルズ・インコーポレーテッド ハプロタイプデータの入手および使用のための方法
US20020077756A1 (en) * 1999-11-29 2002-06-20 Scott Arouh Neural-network-based identification, and application, of genomic information practically relevant to diverse biological and sociological problems, including drug dosage estimation
AU2001231091A1 (en) * 2000-01-21 2001-07-31 Vincent P. Stanton Jr. Identification of genetic components of drug response
US6931326B1 (en) * 2000-06-26 2005-08-16 Genaissance Pharmaceuticals, Inc. Methods for obtaining and using haplotype data
WO2002016643A2 (en) * 2000-08-18 2002-02-28 Curagen Corporation Dna pooling methods for quantitative traits using unrelated populations or sib pairs
US20020098498A1 (en) 2000-09-29 2002-07-25 Bader Joel S. Method of identifying genetic regions associated with disease and predicting responsiveness to therapeutic agents
US6828103B2 (en) 2001-02-22 2004-12-07 Wake Forest University Genetic polymorphisms of estrogen receptor alpha associated with favorable response to hormone replacement therapy
AU2002322775A1 (en) 2001-07-27 2003-02-17 The Regents Of The University Of California Stk15 (stk6) gene polymorphism and methods of determining cancer risk
US20040086886A1 (en) 2001-09-11 2004-05-06 Goldstein Steven A.N. Polymorphisms associated with cardiac arrythmia
US20030162207A1 (en) * 2001-12-14 2003-08-28 Comings David E. Multi-gene tests with ROC plots for the assessment of risk for polygenic disorders
WO2003060652A2 (en) * 2002-01-15 2003-07-24 Vanderbilt University Method and apparatus for multifactor dimensionality reduction
US20040115701A1 (en) 2002-08-30 2004-06-17 Comings David E Method for risk assessment for polygenic disorders
US20050118117A1 (en) 2002-11-06 2005-06-02 Roth Richard B. Methods for identifying risk of melanoma and treatments thereof
US20050032066A1 (en) 2003-08-04 2005-02-10 Heng Chew Kiat Method for assessing risk of diseases with multiple contributing factors
US20050037366A1 (en) 2003-08-14 2005-02-17 Joseph Gut Individual drug safety
US7470513B2 (en) 2003-11-10 2008-12-30 Academia Sinica Risk assessment for adverse drug reactions
US7127355B2 (en) * 2004-03-05 2006-10-24 Perlegen Sciences, Inc. Methods for genetic analysis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232398A1 (en) * 2002-03-28 2003-12-18 Macmurray James P. Use of ROC plots of genetic risk factor to predict risk of sporadic breast cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6012003799; 分子心血管病，　（２００２），　３，　［５］，　ｐ．６０３-６０８ *
JPN6012003802; 臨床病理，　（２００２），　５０，　［１２］，　ｐ．１１２４-１１２９ *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016155840A (ja) * 2009-09-29 2016-09-01 ノバルティス アーゲー Ｓ１ｐ受容体モジュレーターの投与計画
JP2018172401A (ja) * 2009-09-29 2018-11-08 ノバルティス アーゲー Ｓ１ｐ受容体モジュレーターの投与計画
JP2020203892A (ja) * 2009-09-29 2020-12-24 ノバルティス アーゲー Ｓ１ｐ受容体モジュレーターの投与計画
JP7185426B2 (ja) 2009-09-29 2022-12-07 ノバルティス アーゲー Ｓ１ｐ受容体モジュレーターの投与計画
JP2019216732A (ja) * 2010-11-01 2019-12-26 ジェネンテック， インコーポレイテッド 多遺伝子スコアを用いた後期加齢性黄斑変性症への進行の予測
JPWO2022080389A1 (https=) * 2020-10-14 2022-04-21
WO2022080389A1 (ja) * 2020-10-14 2022-04-21 Ｃｒａｉｆ株式会社 観測値の確からしさを評価する方法、及びプログラム

Also Published As

Publication number Publication date
JP2013240344A (ja) 2013-12-05
WO2005086770A2 (en) 2005-09-22
JP2016082984A (ja) 2016-05-19
US7127355B2 (en) 2006-10-24
WO2005086770A9 (en) 2006-10-26
EP1725967A2 (en) 2006-11-29
US20050196770A1 (en) 2005-09-08
EP1725967A4 (en) 2008-01-02
WO2005086770A3 (en) 2006-08-10
US20070037198A1 (en) 2007-02-15

Similar Documents

Publication Publication Date Title
US7127355B2 (en) Methods for genetic analysis
EP2772553B1 (en) Methods for genetic analysis
Hoffmann et al. A large multiethnic genome-wide association study of adult body mass index identifies novel loci
Eggert et al. Genome-wide linkage and association analyses implicate FASN in predisposition to uterine leiomyomata
KR101459057B1 (ko) 임신성 당뇨병 이후 제2형 당뇨병 발병 예측 방법
US20130338012A1 (en) Genetic risk factors of sick sinus syndrome
JP2009541336A (ja) アルツハイマー病の進行に関するバイオマーカー
Mouton et al. MYBPH acts as modifier of cardiac hypertrophy in hypertrophic cardiomyopathy (HCM) patients
WO2018045240A1 (en) Methods and composition for the prediction of the activity of enzastaurin
Gusev Germline mechanisms of immunotherapy toxicities in the era of genome‐wide association studies
Caskey Using genetic diagnosis to determine individual therapeutic utility
JP2018164451A (ja) シミになり易さを判定する方法
JP2018164452A (ja) ソバカスになり易さを判定する方法
CN1950826A (zh) 遗传分析的方法
Hong et al. Identification of pleiotropic genetic variants affecting osteoporosis risk in a Korean elderly cohort
CN108753959A (zh) 一种位于disc1fp1基因的与放疗引起的放射性脑损伤相关的snp标志物及其应用
WO2025014806A1 (en) Multiple-ancestry polygenic risk assessment for breast cancer
CN106929581B (zh) 单核苷酸多态性rs7576984和rs2066802在检测结核易感性中的应用
JP2026047651A (ja) 縄文祖先検査用バイオマーカー
JP2019033739A (ja) 二重まぶたである可能性の高さを判定する方法
JP2019030289A (ja) 毛深さを判定する方法
WO2019153241A1 (zh) 与主要不良心血管事件相关的单核苷酸多态性位点及其应用
CN108715895A (zh) 一种位于kctd1基因的与放疗引起的放射性脑损伤相关的snp标志物及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080226

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110415

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120413

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120420

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130321

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130722

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130723

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130912

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20130919

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20140226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140226

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150106

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20150413